Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
- Title
- Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
- Author
- 이경민
- Keywords
- breast cancer; HER2; HER3; molecular dynamics; neratinib; personalized structural biology; PI3K; precision oncology; Rosetta
- Issue Date
- 2021-08
- Publisher
- CELL PRESS
- Citation
- CANCER CELL, v. 39, NO. 8, Page. 1099-1114
- Abstract
- Activating mutations in HER2 (ERBB2) drive the growth of a subset of breast and other cancers and tend to co-occur with HER3 (ERBB3) missense mutations. The HER2 tyrosine kinase inhibitor neratinib has shown clinical activity against HER2-mutant tumors. To characterize the role of HER3 mutations in HER2-mutant tumors, we integrate computational structural modeling with biochemical and cell biological analyses. Computational modeling predicts that the frequent HER3(E928G) kinase domain mutation enhances the affinity of HER2/HER3 and reduces binding of HER2 to its inhibitor neratinib. Co-expression of mutant HER2/HER3 enhances HER2/HER3 co-immunoprecipitation and ligand-independent activation of HER2/HER3 and PI3K/AKT, resulting in enhanced growth, invasiveness, and resistance to HER2-targeted therapies, which can be reversed by combined treatment with PI3K alpha inhibitors. Our results provide a mechanistic rationale for the evolutionary selection of co-occurring HER2/HER3 mutations and the recent clinical observations that HER3 mutations are associated with a poor response to neratinib in HER2-mutant cancers.
- URI
- https://www.sciencedirect.com/science/article/pii/S1535610821002841?via%3Dihubhttps://repository.hanyang.ac.kr/handle/20.500.11754/177900
- ISSN
- 1535-6108;1878-3686
- DOI
- 10.1016/j.ccell.2021.06.001
- Appears in Collections:
- COLLEGE OF NATURAL SCIENCES[S](자연과학대학) > LIFE SCIENCE(생명과학과) > Articles
- Files in This Item:
- Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.pdfDownload
- Export
- RIS (EndNote)
- XLS (Excel)
- XML